Multivariable analysis of risk factors associated with mortality in the general AML population
| Risk factor . | HR (95% CI)∗ . | P . |
|---|---|---|
| Augmented HCT-CI | ||
| 0-1 | 1.0 | |
| 2-3 | 1.79 (1.05-3.06) | .03 |
| 4-5 | 2.42 (1.44-4.07) | .0009 |
| ≥6 | 3.69 (2.24-6.06) | <.0001 |
| Age, y | ||
| 0-59 | 1.0 | |
| 60-64 | 1.50 (1.05-2.13) | .02 |
| 65-69 | 1.36 (0.99-1.86) | .06 |
| ≥70 | 2.19 (1.65-2.91) | <.0001 |
| ELN cytogenetic risk† | ||
| Low | 1.0 | |
| Intermediate | 1.53 (1.03-2.28) | .03 |
| Adverse | 2.35 (1.56-3.54) | <.0001 |
| Status at enrollment | ||
| Newly diagnosed AML | 1.0 | |
| Relapsed/refractory AML | 1.65 (1.24-2.20) | .0005 |
| Status after treatment | ||
| Never reached CR | 1.0 | |
| CR1 | 0.29 (0.23-0.37) | <.0001 |
| Relapsed after CR1 | 1.66 (1.24-2.23) | .0007 |
| CR2 | 0.78 (0.44-1.37) | .38 |
| Relapsed after CR2 | 3.41 (1.81-6.44) | .0002 |
| CR3 | 3.80 (1.19-12.07) | .02 |
| FACT-G (per 10 points)‡ | 0.89 (0.81-0.98) | .02 |
| PHQ-9 depressive symptoms (per point) | 1.03 (1.00-1.06) | .03 |
| ADL (per point) | 0.95 (0.90-1.00) | .05 |
| 4-MWT mean time (per doubling) | 1.31 (1.09-1.57) | .004 |
| Risk factor . | HR (95% CI)∗ . | P . |
|---|---|---|
| Augmented HCT-CI | ||
| 0-1 | 1.0 | |
| 2-3 | 1.79 (1.05-3.06) | .03 |
| 4-5 | 2.42 (1.44-4.07) | .0009 |
| ≥6 | 3.69 (2.24-6.06) | <.0001 |
| Age, y | ||
| 0-59 | 1.0 | |
| 60-64 | 1.50 (1.05-2.13) | .02 |
| 65-69 | 1.36 (0.99-1.86) | .06 |
| ≥70 | 2.19 (1.65-2.91) | <.0001 |
| ELN cytogenetic risk† | ||
| Low | 1.0 | |
| Intermediate | 1.53 (1.03-2.28) | .03 |
| Adverse | 2.35 (1.56-3.54) | <.0001 |
| Status at enrollment | ||
| Newly diagnosed AML | 1.0 | |
| Relapsed/refractory AML | 1.65 (1.24-2.20) | .0005 |
| Status after treatment | ||
| Never reached CR | 1.0 | |
| CR1 | 0.29 (0.23-0.37) | <.0001 |
| Relapsed after CR1 | 1.66 (1.24-2.23) | .0007 |
| CR2 | 0.78 (0.44-1.37) | .38 |
| Relapsed after CR2 | 3.41 (1.81-6.44) | .0002 |
| CR3 | 3.80 (1.19-12.07) | .02 |
| FACT-G (per 10 points)‡ | 0.89 (0.81-0.98) | .02 |
| PHQ-9 depressive symptoms (per point) | 1.03 (1.00-1.06) | .03 |
| ADL (per point) | 0.95 (0.90-1.00) | .05 |
| 4-MWT mean time (per doubling) | 1.31 (1.09-1.57) | .004 |
4-MWT, National Institutes of Health Toolbox 4-Meter Walk Gait Speed Test; ADL, activities of daily living; FACT-G, functional assessment of cancer therapy–general; PHQ-9, patient health questionnaire 9; HR, hazard ratio; CI, confidence interval.
Cox regression analysis based on time since start of treatment on enrolled study.
Missing data indicator included.
For time-dependent QOL measures, missing data indicator until first known data and analysis uses last available observation.